Because evidence suggests that both Src and FAK mediate the aggressive behavior of pancreatic cancer cells and that they form a dual signaling pathway (Figs. 5 and 6), it might be beneficial to study whether a combination of Src and FAK inhibitors, with or without other current therapeutic agents, will enhance their overall efficacy to limit pancreatic cancer progression in vivo. The gene discussed is PTK2; the disease is familial pancreatic carcinoma.